Cheshire, Conn., USA - September 18, 2014, Cheshire, Conn., USA - Alexion Pharmaceuticals, Inc., a biopharmaceutical company, announced key measures to strengthen and broaden its executive leadership team.
Article continues below
David Hallal is being promoted to the newly created position of Chief Operating Officer and has been appointed to Alexion’s Board of Directors.
Mr. Hallal joined Alexion in 2006 to initiate the Company’s U.S. commercial operations, and has played the principal role in building Alexion’s successful global commercial platform to serve patients with severe and life-threatening rare disorders. From his initial role where he led the highly successful U.S. launch of the Company's first product, Soliris (eculizumab) in 2007, Mr. Hallal has progressively expanded his responsibilities to Chief Commercial Officer.
In addition to his leadership of all commercial operations globally, Mr. Hallal has responsibility for country operations in each of Alexion’s affiliates in EMEA, Japan, Australasia, Latin America. Mr. Hallal serves on all key management decision-making committees.
He has more than 25 years of experience in the biopharmaceutical industry, and prior to Alexion he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen. Mr. Hallal holds a B.A. from the University of New Hampshire.
Clare Carmichael is being promoted to Executive Vice President and Chief Human Resources Officer (CHRO) from her previous position of Senior Vice President and CHRO.
Ms. Carmichael will continue to lead and significantly expand the Company’s global talent initiatives including talent management, talent acquisition, training and development, and compensation and benefits.
Ms. Carmichael joined Alexion in 2011. Ms. Carmichael has 30 years of HR leadership experience in global pharmaceutical and biotech organizations, and prior to Alexion, she held leadership positions at Watson Pharmaceuticals, Schering-Plough Corporation, Eyetech Pharmaceuticals, and Pharmacia Corporation. Ms. Carmichael received a bachelor’s degree from Rider University and completed the University of Michigan Human Resources Executive Program.
John Moriarty, J.D. is being promoted to Executive Vice President and General Counsel from his previous position of Senior Vice President and General Counsel.
Mr. Moriarty will continue to lead all of the Company’s legal, government affairs and corporate communications activities, further expanding each of these functions to support the Company’s ongoing global growth.
Mr. Moriarty joined Alexion in 2012 and has provided significant leadership across his areas of responsibility including all global legal matters as well as the Global Government Affairs and Corporate Communications teams.
Prior to joining Alexion, Mr. Moriarty was General Counsel and Chief Legal Officer at Elan Corporation plc, and held several legal leadership positions at Amgen, was an attorney in the healthcare practice of a national law firm’s Washington, D.C. and New York offices, and was a healthcare fraud prosecutor in the U.S. Attorney’s Office and the Virginia Attorney General’s Office. He holds a J.D. from the University of Georgia School of Law and a B.A. from the University of Virginia.
Additionally, the Company announces that Edward Miller, J.D. has joined Alexion in the newly created position of Senior Vice President and Chief Compliance Officer.
From 2000 to 2013, Mr. Miller held numerous compliance and legal leadership positions at Boehringer Ingelheim Pharmaceuticals/Boehringer Ingelheim GmbH, including Vice President, Associate General Counsel, Global Litigation & Government Investigations, Vice President/Acting Global Compliance Officer, Vice President, Chief Compliance Officer and Head of Litigation, and Chief Compliance Officer, Head of Litigation. ■